Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TrkA receptor antagonist

DRUG CLASS:

TrkA receptor antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

taletrectinib (5)

taletrectinib (5)

›

ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	taletrectinib Sensitive: B - Late Trials taletrectinib Sensitive : B	taletrectinib Sensitive: B - Late Trials taletrectinib Sensitive : B
CD74-ROS1 fusion	Non Small Cell Lung Cancer	CD74-ROS1 fusion	Non Small Cell Lung Cancer	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	taletrectinib Sensitive: C3 – Early Trials taletrectinib Sensitive : C3	taletrectinib Sensitive: C3 – Early Trials taletrectinib Sensitive : C3
TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	taletrectinib Sensitive: C4 – Case Studies taletrectinib Sensitive : C4	taletrectinib Sensitive: C4 – Case Studies taletrectinib Sensitive : C4
FLT3 G697R	Acute Myelogenous Leukemia	FLT3 G697R	Acute Myelogenous Leukemia	K-252a Sensitive: D – Preclinical K-252a Sensitive : D	K-252a Sensitive: D – Preclinical K-252a Sensitive : D